» Articles » PMID: 39698291

A High-Throughput and Logarithm-Serial-Dilution Microfluidic Chip for Combinational Drug Screening on Tumor Organoids

Overview
Specialty Biochemistry
Date 2024 Dec 19
PMID 39698291
Authors
Affiliations
Soon will be listed here.
Abstract

Tumor organoids are biological models for studying precision medicine. Microfluidic technology offers significant benefits for high throughput drug screening using tumor organoids. However, the range of concentrations achievable with traditional linear gradient generators in microfluidics is restricted, generating logarithmic drug concentration gradients by adjusting the channel ratio in the chip is confined to single-drug dilution chips, significantly restricting the application of microfluidics in drug screening. Here, we presented a microfluidic chip featuring continuous dilution capabilities, which generates logarithmic stepwise drug concentration gradients. We have devised a "mathematical-circuit-chip" model for designing such chips, and based on this model, we have developed and fabricated a device capable of providing 36 distinct drug concentration conditions for two types of drugs. The chip is composed of two structurally identical yet orthogonally arranged layers, each containing a dilution network capable of forming a 5-fold gradient and a tumor organoid culture module. Drug and culture medium delivery to the open culture chamber array is driven by syringe pumps. We have conducted drug screening experiments on patient-derived tumor organoids. This device facilitates high-throughput drug screening for patient-derived organoids, representing a significant stride toward the realization of precision medicine.

References
1.
Takara K, Sakaeda T, Yagami T, Kobayashi H, Ohmoto N, Horinouchi M . Cytotoxic effects of 27 anticancer drugs in HeLa and MDR1-overexpressing derivative cell lines. Biol Pharm Bull. 2002; 25(6):771-8. DOI: 10.1248/bpb.25.771. View

2.
Wang L, Wang X, Wang T, Zhuang Y, Wang G . Multi-omics analysis defines 5-fluorouracil drug resistance in 3D HeLa carcinoma cell model. Bioresour Bioprocess. 2024; 8(1):135. PMC: 10991626. DOI: 10.1186/s40643-021-00486-z. View

3.
Saorin G, Caligiuri I, Rizzolio F . Microfluidic organoids-on-a-chip: The future of human models. Semin Cell Dev Biol. 2022; 144:41-54. DOI: 10.1016/j.semcdb.2022.10.001. View

4.
Hofer M, Lutolf M . Engineering organoids. Nat Rev Mater. 2021; 6(5):402-420. PMC: 7893133. DOI: 10.1038/s41578-021-00279-y. View

5.
Yu L, Li Z, Mei H, Li W, Chen D, Liu L . Patient-derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CAR-T cells . Clin Transl Immunology. 2021; 10(2):e1248. PMC: 7847802. DOI: 10.1002/cti2.1248. View